Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Aardvark Therapeutics Inc (AARD)

Aardvark Therapeutics Inc (AARD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Aardvark Therapeutics Announces First Patient Dosed in Australia in HERO Phase 3 Trial for Prader-Willi Syndrome GlobeNewswire - Wed Dec 10, 2025

Multiple active sites and strong US enrollment continue to support Q3 2026 timing for topline data readout Clinical trial sites in Canada and the United Kingdom have received regulatory clearance...

AARD : 15.52 (+0.98%)
Aardvark Therapeutics to Present at Upcoming Investor Conferences in December GlobeNewswire - Tue Nov 25, 2025

SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics...

AARD : 15.52 (+0.98%)
Aardvark Therapeutics Reports Third Quarter 2025 Financial Results and Provides Pipeline and Business Updates GlobeNewswire - Thu Nov 13, 2025

Aardvark has aligned with the FDA to reduce the minimum age of eligibility from 13 to 10 years old for pediatric patients in HERO, the Phase 3 trial of ARD-101 for the treatment of hyperphagia associated...

AARD : 15.52 (+0.98%)
Aardvark Therapeutics Presents Data Supporting its Metabolic Obesity Pipeline Programs at ObesityWeek 2025 GlobeNewswire - Tue Nov 4, 2025

New preclinical results demonstrate the potential of ARD-201 in enhanced glucose control, along with preservation of lean mass, underscoring its opportunity in addressing key challenges in today’s obesity...

AARD : 15.52 (+0.98%)
Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) GlobeNewswire - Mon Nov 3, 2025

SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics...

AARD : 15.52 (+0.98%)
Aardvark Therapeutics to Present at Upcoming Investor Conferences in November GlobeNewswire - Mon Nov 3, 2025

SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics...

AARD : 15.52 (+0.98%)
Aardvark Therapeutics to Present Data on Pipeline Programs at Upcoming ObesityWeek GlobeNewswire - Wed Oct 22, 2025

SAN DIEGO, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics...

AARD : 15.52 (+0.98%)
Aardvark Therapeutics Aligns with FDA on Trial Amendment Tipranks - Fri Oct 10, 2025

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Aardvark...

AARD : 15.52 (+0.98%)
Aardvark Therapeutics Announces FDA Alignment on Protocol Amendment Expanding Phase 3 HERO Trial Population for Prader-Willi Syndrome GlobeNewswire - Wed Oct 8, 2025

SAN DIEGO, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics...

AARD : 15.52 (+0.98%)
Aardvark Therapeutics to Present at the Stifel 2025 Virtual Cardiometabolic Forum GlobeNewswire - Tue Sep 23, 2025

SAN DIEGO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics...

AARD : 15.52 (+0.98%)

Barchart Exclusives

Trump’s Greenland Threats Scaring You Off? Buy This Dividend Stock as a Hedge Barchart - Tue Jan 20, 6:30PM CST
Trump's threats to seize Greenland have led to a selloff in risk assets while precious metals have rallied amid the flight to safe-haven assets. Agnico-Eagle Mines is a good dividend stock to buy amid the geopolitical turmoil. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot